menu
    • menu
    [{"orgOrder":0,"company":"Stelis Biopharma","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"rAd26","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Stelis Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Stelis Biopharma \/ RDIF","highestDevelopmentStatusID":"12","companyTruncated":"Stelis Biopharma \/ RDIF"},{"orgOrder":0,"company":"Stelis Biopharma","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Termination","leadProduct":"AKS-452","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Stelis Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Stelis Biopharma \/ Stelis Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"Stelis Biopharma \/ Stelis Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Stelis Biopharma

    Menu

    Stelis Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stelis Biopharma

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Stelis Biopharma

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AKS-452

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Akston Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Akston Biosciences Ends Vaccine Partnership with Stelis, Continues to Advance COVID Universal Booster EUA

                            Details : Akston has reclaimed all rights to AKS-452, a room temperature stable, low-cost, protein subunit COVID-19 vaccine. Akston is continuing its progress to secure Emergency Use Authorization (EUA) in India and has begun working with a new CDMO to produce AKS...

                            Brand Name : AKS-452

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 07, 2023

                            Lead Product(s) : AKS-452

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Akston Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Stelis Biopharma

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Stelis Biopharma

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rAd26

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Russian Direct Investment Fund

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Stelis Biopharma Gets CDSCO Nod to Export 50 Million Doses of Sputnik Light Vaccine

                            Details : Sputnik Light (rAd26) vaccine demonstrates 91.6% efficacy rate against coronavirus, the world’s first registered vaccine against the novel coronavirus infection, is now approved for use in over 50 countries.

                            Brand Name : Sputnik Light

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 21, 2021

                            Lead Product(s) : rAd26

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Russian Direct Investment Fund

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth